scispace - formally typeset
Open AccessJournal ArticleDOI

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.

TLDR
This work investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails.
Abstract
Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 (COVID-19) pandemic; however, concerns remain that mutations can yield antibody resistance. We investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails. These antibodies remain effective against spike variants that have arisen in the human population. However, novel spike mutants rapidly appeared after in vitro passaging in the presence of individual antibodies, resulting in loss of neutralization; such escape also occurred with combinations of antibodies binding diverse but overlapping regions of the spike protein. Escape mutants were not generated after treatment with a noncompeting antibody cocktail.

read more

Citations
More filters
Posted ContentDOI

High affinity modified ACE2 receptors prevent SARS-CoV-2 infection

TL;DR: In this paper, a decoy ACE2 decoy with directed evolution was used to develop a SARS-CoV-2 neutralizing drug that has affinity comparable to monoclonal antibodies yet displaying resistance to escape mutations of virus.
Journal ArticleDOI

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19

TL;DR: In this article , a living systematic review was conducted to assess the effects of SARS-CoV-2-neutralizing mAbs, including mAb fragments, to prevent infection with SARS•CoV•2 causing COVID•19.
Journal ArticleDOI

Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants

TL;DR: Cryo-EM complex structures reveal that dromedary camel VHH nanobody binds the S1 subunit of the viral spike protein, and the other (7A3) targets a deeply buried region that uniquely extends to the S2 subunit beyond the S 1 subunit, suggesting the therapeutic potential of these nanobodies against COVID-19.
Journal ArticleDOI

SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19

TL;DR: This protocol is a protocol for a Cochrane Review (intervention) to assess the effectiveness and safety of SARS-CoV-2-neutralising mAbs, including mAb fragments, and to maintain the currency of the evidence using a living systematic review approach.
Journal ArticleDOI

Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines.

TL;DR: In this article, the authors discuss the different monoclonal antibody and vaccine therapies available against COVID-19 and how the efficacy of these therapies is affected by the emergence of variants of SARS-CoV-2.
References
More filters
Journal ArticleDOI

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

TL;DR: Cryo–electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein of SARS-CoV-2 are presented, providing important insights into the molecular basis for coronavirus recognition and infection.
Journal ArticleDOI

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.

TL;DR: The crystal structure of the C-terminal domain of SARS-CoV-2 (SARS- coV- 2-CTD) spike (S) protein in complex with human ACE2 (hACE2) is presented, which reveals a hACE2-binding mode similar overall to that observed for SARS -CoV.
Journal ArticleDOI

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Related Papers (5)